CliffBio
small molecule

TROXYCA ER

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Loss of exclusivityDecember 2027latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameTROXYCA ER
Active ingredientNALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Strength4.8MG;40MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
7815934December 2027product

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TROXYCA ER patent cliff — loss of exclusivity December 2027 | CliffBio